Skip to content
TrialScanner

NCT04505826

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

Phase 1/Phase 2CompletedOLMALead

Registry record

Lead sponsor
Olema Oncology, Inc.
Conditions
Hormone Receptor Positive Breast Carcinoma; HER2-negative Breast Cancer
Primary completion
Jul 30, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04505826 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04505826: A Dose Escalation/Expansion... | TrialScanner